Stryker Corporation $SYK Shares Purchased by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Stryker stake by 263% in the second quarter, purchasing 28,037 additional shares and bringing its holdings to 38,699 shares valued at approximately $12.2 million. Institutional investors collectively own 77.09% of SYK.
• Stryker reported quarterly EPS of $3.69, beating estimates by $0.20, while revenue rose 9.4% year over year to $6.59 billion. The company guided to fiscal 2026 EPS of $14.95–$15.10.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $386.28, compared with the shares’ opening price of $345.05. Stryker also declared a quarterly dividend of $0.88 per share, yielding approximately 1.0% annually.

Assenagon Asset Management S.A. raised its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 263.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,699 shares of the medical technology company's stock after acquiring an additional 28,037 shares during the period. Assenagon Asset Management S.A.'s holdings in Stryker were worth $12,184,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of SYK. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker in the 4th quarter valued at $26,000. Sankala Group LLC purchased a new stake in Stryker during the 4th quarter worth $26,000. United Financial Planning Group LLC purchased a new stake in Stryker during the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. acquired a new stake in Stryker in the 4th quarter valued at $27,000. Finally, DJE Kapital AG purchased a new position in Stryker in the fourth quarter valued at about $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.60% of the company's stock.

Stryker Price Performance

Shares of NYSE SYK opened at $345.05 on Tuesday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $132.35 billion, a price-to-earnings ratio of 35.76, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The business has a 50 day simple moving average of $321.03 and a 200-day simple moving average of $333.81.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio is currently 36.48%.

Analysts Set New Price Targets

Several equities research analysts recently commented on SYK shares. Citigroup reiterated an "outperform" rating on shares of Stryker in a report on Monday, August 3rd. Evercore set a $350.00 price objective on shares of Stryker in a research note on Monday, July 6th. Weiss Ratings reissued a "hold (c)" rating on shares of Stryker in a research report on Friday, July 31st. Barclays lowered their target price on Stryker from $469.00 to $394.00 and set an "overweight" rating for the company in a research note on Monday, May 4th. Finally, Robert W. Baird set a $385.00 target price on Stryker in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and an average price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source